Dr. Emily C. Ayers, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Columbia University College of Physicians and Surgeons (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 245
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Columbia University College of Physicians and Surgeons
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
VA license 0101270143 -
Medical Oncology Physician
VA license 0101270143
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Virginia Medical Center Charlottesville, VA
- Bon Secours St Marys Hospital Richmond, VA
- Centra Health - Lynchburg Gen Hospital Lynchburg, VA
Medical groups
- University of Virginia Physicians Group (1,717 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 245
- Services billed
- 757
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 227 | 115 |
| Established patient office or other outpatient visit, 30-39 minutes | 185 | 130 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 184 | 49 |
| New patient office or other outpatient visit, 60-74 minutes | 70 | 70 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 39 | 38 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Charlottesville, VA | 84 |
| Acyclovir Other prescribers in Charlottesville, VA | 53 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Charlottesville, VA | 38 |
| Brukinsa (zanubrutinib) | 29 |
| Ondansetron Hcl Other prescribers in Charlottesville, VA | 27 |
| Eliquis (apixaban) Other prescribers in Charlottesville, VA | 22 |
| Allopurinol Other prescribers in Charlottesville, VA | 20 |
| Calquence (acalabrutinib maleate) | 18 |
| Hydroxyzine Hcl Other prescribers in Charlottesville, VA | 18 |
| Dexamethasone Other prescribers in Charlottesville, VA | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 8 payments worth $4,006 in total to this clinician.
| Incyte Corporation | $1,974 |
|---|---|
| Genentech USA, Inc. | $1,605 |
| Genmab U.S., Inc. | $203 |
| Adc Therapeutics America, Inc. | $142 |
| Pfizer Inc. | $82.23 |
| Consulting Fee | $3,530 |
|---|---|
| Food and Beverage | $476 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $1,925 |
| Genentech USA, Inc. Mar 24, 2025 | Consulting Fee Lunsumio; Polivy · BioOncology | $1,605 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $380,856 in research payments for these studies, mostly to the institutions running them.
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06091254 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in …
Incyte Corporation - A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Eli Lilly and Company · Active, not recruiting · NCT04965493 - A study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with other anti-cancer agents in participants with relapsed or refractory b-cell non-hodgkin lymphoma (LOTIS-7)
Adc Therapeutics America, Inc. - A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
AbbVie Inc. · Active, not recruiting · NCT05578976 - M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
AbbVie Inc. - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.